CAR-T cell therapy for pediatric solid tumors: armored CAR-T cells and beyond - PubMed
5 hours ago
- #Pediatric Oncology
- #CAR-T
- #Immunotherapy
- CAR-T cell therapy is a promising treatment for hematologic malignancies in children and adults.
- CAR-T cells are FDA-approved for six hematologic malignancies but have limited success in solid tumors.
- Challenges in solid tumors include hostile tumor microenvironment (TME), poor CAR-T persistence, and targeting difficulties.
- Armored CAR-T cells, which modify the TME via secreted cytokines, show early success in pediatric solid tumors.
- Recent trials focus on pediatric solid malignancies like Ewing sarcoma, neuroblastoma, and others.
- Innovative approaches are rapidly being developed to address limitations of CAR-T therapy in solid tumors.